Skip to main content
European Commission logo print header

Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Project description

Next-generation influenza vaccines

The strategic goals of the EU-funded INCENTIVE project are to advance knowledge of the underlying mechanisms of poor responsiveness to influenza vaccines (IVs) and to develop two next-generation universal IVs. This is a partnership between Indian, European and US groups that address the global health and economic challenge posed by influenza infections. The objectives include: performing comprehensive profiling of responders and non-responders to licensed IVs in infants, children, adults and elderly in phase IV trials in Europe and India to identify the mechanisms of vaccine responsiveness; advancing the development of two next-generation vaccines by providing a proof-of-concept for vaccine efficacy in non-human primates for an antigen presenting cell-targeted nucleic acid vaccine and developing a computationally-optimized vaccine up to phase II clinical trials and vaccine efficacy in a controlled human challenge; identifying predictive biomarkers of responsiveness to vaccination for new diagnostics; implementing technology transfer; and performing a health systems and investment analysis.

Objective

The highly integrated INCENTIVE consortium represents true partnership between Indian and European/US groups that addresses the global health and economic challenge posed by influenza infections, to reduce the worldwide burden resulting from outbreaks. INCENTIVE’s strategic goals are to provide seminal knowledge on the underlying mechanisms of poor responsiveness to influenza vaccines in vulnerable individuals and advance the development of two next generation universal influenza vaccines. This is achieved by pursing the following specific objectives: 1) address the current knowledge gap by performing comprehensive immunome profiling of responders and non-responders to licensed influenza vaccines in infants, children, adults and elderly in parallel phase IV trials in Europe and India to identify the underlying mechanisms of vaccine responsiveness in different vulnerable populations and ethnical groups; 2) advance the development of two next generation universal vaccines, including an antigen presenting cell-targeted nucleic acid vaccine up to proof-of-concept for vaccine efficacy in non-human primates, and a computationally-derived second generation COBRA (Computationally-Optimized Broadly-Reactive Antigens) vaccine up to clinical development, comprising a phase I trial in Europe, a phase II trial in India and efficacy studies using an influenza controlled human challenge model; 3) identify predictive biomarkers of responsiveness to vaccination to develop new diagnostics; 4) implement comprehensive technology transfer and harmonization activities for immunological analysis and data integration; and 5) perform a health systems and investment analysis, and discrete choice experiments to assess the suitability of the developed technologies for low- and middle-income countries and to identify potential downstream constraints that might affect uptake by health care systems.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Single-Stage-RTD

Coordinator

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Net EU contribution
€ 2 537 797,50
Address
INHOFFENSTRASSE 7
38124 Braunschweig
Germany

See on map

Region
Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
€ 2 537 797,50

Participants (20)